Objective:
To evaluate the diagnostic efficacy of chlamydia culture, direct immunofluorescence (DFA), direct enzyme immunoassay (EIA), polymerase chain reaction (PCR) and serology by defining positive culture or at least two positive non-culture tests as true positive.
Setting:
Three gynaecological departments located in separate areas of Sweden.
Patients And Design:
All pregnant women requesting abortion during a six month period were included. In cases with unconfirmed non-culture tests, reculture with multiple passage and PCR on the culture transport medium was performed for confirmation. Serum was analysed for chlamydial antibodies type IgG, IgM and IgA using microimmunofluorescence.
Results:
18 of 419 (4.3%) patients were positive for chlamydia according to the defined criteria. Twelve of 419 (2.9%) were positive in standard culture (primary inoculation). The sensitivity of standard culture, DFA, EIA and PCR were 66.7%, 77.8%, 64.7% and 71.4% respectively. The specificity 100% (by definition), 99.5%, 100%, 100% respectively. The positive predictive value 100% (by definition), 87.5%, 100%, 100% respectively. Negative predictive value 98.5%, 99.0%, 98.5%, 98.9% respectively. Serum IgG titre of > or = 64 and > or = 1024 gave positive predictive values of 10% and 21% respectively.
Conclusions:
When an expanded gold standard is used, the specificity and positive predictive value of the non-culture tests used are comparable with that of standard culture even in this low prevalence population. Standard culture underestimated the chlamydia prevalence by 33%. The prevalence found represents a decrease from 10 to 2.9% of culture verified chlamydia during four years in comparable populations. Chlamydial antibodies of certain immunological classes are not necessarily present in cases with chlamydia.
Citing Articles
Chlamydia trachomatis and Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health.
Ljubin-Sternak S, Mestrovic T
J Pathog. 2015; 2014:183167.
PMID: 25614838
PMC: 4295611.
DOI: 10.1155/2014/183167.
Screening tests: a review with examples.
Maxim L, Niebo R, Utell M
Inhal Toxicol. 2014; 26(13):811-28.
PMID: 25264934
PMC: 4389712.
DOI: 10.3109/08958378.2014.955932.
Genital Chlamydia trachomatis: an update.
Malhotra M, Sood S, Mukherjee A, Muralidhar S, Bala M
Indian J Med Res. 2013; 138(3):303-16.
PMID: 24135174
PMC: 3818592.
Seropositivity of Chlamydia trachomatis among saudi pregnant women in makkah.
Ghazi H, Daghestani M, Mohamed M
J Family Community Med. 2012; 13(2):61-4.
PMID: 23012106
PMC: 3410065.
Chlamydia trachomatis diagnostics.
Chernesky M
Sex Transm Infect. 2002; 78(4):232-4.
PMID: 12181457
PMC: 1744520.
DOI: 10.1136/sti.78.4.232.
Evaluation of the Biostar Chlamydia OIA assay with specimens from women attending a sexually transmitted disease clinic.
Pate M, Dixon P, Hardy K, Crosby M, Hook 3rd E
J Clin Microbiol. 1998; 36(8):2183-6.
PMID: 9665987
PMC: 105001.
DOI: 10.1128/JCM.36.8.2183-2186.1998.
Evaluation of the microparticle enzyme immunoassay Abbott IMx Select Chlamydia and the importance of urethral site sampling to detect Chlamydia trachomatis in women.
Brokenshire M, Say P, van Vonno A, Wong C
Genitourin Med. 1998; 73(6):498-502.
PMID: 9582469
PMC: 1195933.
DOI: 10.1136/sti.73.6.498.
Lowering the cut off value of an automated chlamydia enzyme immunoassay and confirmation by PCR and direct immunofluorescent antibody test.
Tong C, Donnelly C, Hood N
J Clin Pathol. 1997; 50(8):681-5.
PMID: 9301554
PMC: 500120.
DOI: 10.1136/jcp.50.8.681.
"Does ligase chain reaction assay of urine in the diagnosis of Chlamydia trachomatis offer significant improvement over existing diagnostic tests?"--a critical appraisal of the evidence.
Grun L, Sheldon J
Genitourin Med. 1996; 72(6):435-9.
PMID: 9038643
PMC: 1195735.
DOI: 10.1136/sti.72.6.435.
Detection of Chlamydia trachomatis infections in women by Amplicor PCR: comparison of diagnostic performance with urine and cervical specimens.
Pasternack R, Vuorinen P, Kuukankorpi A, Pitkajarvi T, Miettinen A
J Clin Microbiol. 1996; 34(4):995-8.
PMID: 8815129
PMC: 228938.
DOI: 10.1128/jcm.34.4.995-998.1996.
Comparison of an automated enzyme immunoassay with a direct fluorescent antibody test and polymerase chain reaction for the detection of Chlamydia trachomatis in diagnostic specimens from male patients.
Tong C, Valentine C, Arya O
Eur J Clin Microbiol Infect Dis. 1996; 15(4):336-40.
PMID: 8781887
DOI: 10.1007/BF01695668.
Under-diagnosis of female genital Chlamydia trachomatis infection.
Tong C, Tait I
Genitourin Med. 1996; 72(2):144-5.
PMID: 8698366
PMC: 1195628.
DOI: 10.1136/sti.72.2.144.
Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.
Davies H, Wang E
CMAJ. 1996; 154(11):1631-44.
PMID: 8646651
PMC: 1487928.
Evaluation of Sanofi Diagnostics Pasteur Chlamydia Microplate EIA shortened assay and comparison with cell culture and Syva Chlamydia MicroTrak II EIA in high- and low-risk populations.
Chan E, Brandt K, Horsman G
J Clin Microbiol. 1995; 33(11):2839-41.
PMID: 8576329
PMC: 228590.
DOI: 10.1128/jcm.33.11.2839-2841.1995.
Use of PCR and direct immunofluorescence microscopy for confirmation of results obtained by Syva MicroTrak Chlamydia enzyme immunoassay.
Ostergaard L, Moller J
J Clin Microbiol. 1995; 33(10):2620-3.
PMID: 8567894
PMC: 228542.
DOI: 10.1128/jcm.33.10.2620-2623.1995.
Epidemiology and transmission patterns of concomitant genital chlamydial and gonococcal infections.
Matondo P, Johnson I, Sivapalan S
Genitourin Med. 1995; 71(4):266-7.
PMID: 7590726
PMC: 1195531.
DOI: 10.1136/sti.71.4.266.
Detection of Chlamydia trachomatis in a low prevalence population.
Ostergaard L
Eur J Clin Microbiol Infect Dis. 1995; 14(5):471-2.
PMID: 7556244
DOI: 10.1007/BF02114911.